LIMD2 (LIM domain containing 2) is a LIM-only protein that functions as a direct activator of integrin-linked kinase (ILK), regulating cell motility and cytoskeletal dynamics 1. Structurally, LIMD2 contains a classic LIM domain that binds directly to the kinase domain of ILK near its active site, strongly enhancing ILK kinase activity 1. This interaction links integrin-mediated signaling to cellular invasion and metastatic behavior through multiple pathways including ILK/Akt 2, ERK1/2 3, and focal adhesion signaling 4. LIMD2 is significantly upregulated in multiple human malignancies and correlates with poor prognosis and metastatic potential 1. In cancer contexts, LIMD2 overexpression promotes proliferation, invasion, epithelial-mesenchymal transition (EMT), and migration across diverse tumor types including clear cell renal cell carcinoma, ovarian carcinoma, papillary thyroid cancer, and non-small cell lung cancer 2356. LIMD2 knockdown consistently inhibits these malignant phenotypes 34. Beyond oncology, LIMD2 has been identified as a cell aging-immune/inflammation-related hub gene in acute myocardial infarction 7 and as a dysregulated gene associated with skeletal muscle atrophy 8. These findings position LIMD2 as a potential therapeutic target across multiple disease contexts.